In light of our initial observations, we aimed to evaluate the effects of combining HAMLET with the standard chemotherapy FOLFOX on BRAF mutant CRC cell lines and ex vivo explant models to assess whether the response to HAMLET is driven by the BRAF mutation or by mutation-independent mechanisms such as mitochondrial function. Here, BRAF is linked to colorectal carcinoma.